Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Fundacão D Anna De Sommer Champalimaud E Dr Carlos Montez Champalimaud Foundation manages a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 1 pending office action, which is being handled by 1 distinct examiner. This singular focus indicates that the entity's immediate prosecution efforts are concentrated within a specific technical niche. The involvement of 1 distinct art unit further suggests that the subject matter of the pending application is highly specialized within the broader biotechnology field.
The busiest examiner for this portfolio is JOHANSEN, PETER N., who is responsible for 1 busiest examiner pending action. This figure accounts for the total volume of 1 pending office action currently facing the entity. Because there is only 1 distinct examiner involved, the immediate interaction with the USPTO is limited to a single point of contact. This creates a centralized prosecution environment where the outcome of the pending matter depends entirely on the findings of JOHANSEN, PETER N.
Practitioners should note that the 1:1 ratio between pending actions and distinct examiners means there is no internal baseline for comparing examiner behavior. The concentration in 1 distinct art unit simplifies the regulatory landscape but centralizes the risk of the prosecution strategy on a single examiner's interpretation. Consequently, the 1 busiest examiner pending action handled by JOHANSEN, PETER N. represents the total scope of the current Biotechnology & Pharmaceuticals patent challenges.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHANSEN, PETER N. | 1 | 59.3% | +24.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18096908 | CHIMERIC RECEPTOR POLYPEPTIDE AND METHODS OF ACTIVATION THEREOF | JOHANSEN, PETER N. | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18096908 | CHIMERIC RECEPTOR POLYPEPTIDE AND METHODS OF ACTIVATION THEREOF | JOHANSEN, PETER N. | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18096908 | CHIMERIC RECEPTOR POLYPEPTIDE AND METHODS OF ACTIVATION THEREOF | JOHANSEN, PETER N. | 1644 | §101§102§103§112 | Non-Final OA | — | Pending | Jan 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial